RMTI ROCKWELL MEDICAL, INC.

CIK 0001041024 50 ready 8-Ks latest August 13, 2026, 6:14 AM ET RSS · JSON

Activity: NORMAL 2 filings / 30d vs 1 baseline

Ready 8-Ks 50

Latest filing August 13, 2026, 7:27 AM ET

Top materiality 0.80

Event mix other_material ×18 · earnings ×16 · other ×8

Sentiment 14 pos · 5 neg · 31 neu

Latest earnings reported 2026-Q1

Executive change recent →

SHENANIGAN SCORE 2 / 7 see the board

Recent 8-K filings for RMTI

Highest-materiality recent filing

Rockwell Medical Q3 net sales fall 44% to $15.9M; net loss of $1.8M vs profit year ago

November 12, 2025, 6:59 PM ET earnings materiality 0.80 negative item 2.02 item 9.01

Net sales $15.9M, down 44% YoY due to largest customer transitioning to another supplier.
Net loss of $1.8M compared to net income of $1.7M in Q3 2024; Adjusted EBITDA virtually breakeven at $50k.

Read filing →

August 13, 2026, 6:14 AM ET earnings materiality 0.60 positive item 2.02 item 9.01

Rockwell Medical Q2 net sales up 11% to $17.8M; net loss narrows to $1.2M

Net sales $17.8M, +11% YoY; gross profit $3.2M, +30%; gross margin 18% vs 16%.
July 20, 2026, 6:22 AM ET regulatory materiality 0.60 positive item 8.01 item 9.01

Rockwell Medical regains Nasdaq minimum bid price compliance; listing matter closed

Received Nasdaq notice on July 16, 2026 that bid price compliance is regained under Rule 5550(a)(2).
June 29, 2026, 6:17 AM ET other material materiality 0.60 neutral item 3.03 item 5.03 item 9.01

Rockwell Medical implements 1-for-10 reverse stock split effective July 1, 2026

Reverse stock split ratio 1-for-10; effective 12:01 a.m. ET on July 1, 2026.
June 15, 2026, 4:27 PM ET other material materiality 0.70 neutral item 5.07 ◈ Shareholder Votes ×4

Rockwell Medical stockholders approve reverse stock split, elect directors

Reverse stock split amendment approved: 16,993,038 for, 6,597,036 against, 223,632 abstain.
May 8, 2026, 7:59 PM ET regulatory materiality 0.70 negative item 3.01 ◈ Listing & Compliance Notices

Rockwell Medical receives Nasdaq delisting notice for bid price below $1.00

Notice issued May 8, 2026 for failing to meet $1.00 minimum bid price over 30 consecutive business days.
May 7, 2026, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01 ◈ Earnings Releases ×2

Rockwell Medical Q1 net sales $17.3M (-8% YoY); guides FY26 gross margin 18-22%

Net sales $17.3M, down 8% from $18.9M; net loss $1.6M vs $1.5M in prior year.
March 26, 2026, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01 ◈ Earnings Releases ×2

Rockwell Medical Q4 2025 net sales $18.3M, gross margin 21% (up from 15%), full-year Adj. EBITDA $0.3M

Q4 2025 net sales $18.3M (vs $24.7M Q4 2024); full-year net sales $69.3M (vs $101.5M) driven by reduced customer purchase volumes.
January 20, 2026, 6:59 PM ET earnings materiality 0.60 positive item 2.02 item 9.01

Rockwell Medical prelim Q4 sales ~$18.6M; cash flow positive $2.3M

Preliminary Q4 2025 net sales ~$18.6M; full-year 2025 ~$69.5M (audit pending).
January 5, 2026, 6:59 PM ET other material materiality 0.75 positive item 8.01

Rockwell Medical extends DaVita supply agreement to Dec 2026 with price hike

Second Amendment extends Products Purchase Agreement through Dec 31, 2026.
November 12, 2025, 6:59 PM ET earnings materiality 0.80 negative item 2.02 item 9.01

Rockwell Medical Q3 net sales fall 44% to $15.9M; net loss of $1.8M vs profit year ago

Net sales $15.9M, down 44% YoY due to largest customer transitioning to another supplier.
August 14, 2025, 7:59 PM ET earnings materiality 0.65 negative item 2.02 item 9.01

Rockwell Medical Q2 2025 revenue drops 38% to $16.1M, net loss of $1.5M

Net sales $16.1M, down 38% YoY, driven by loss of largest customer; gross margin 16% in line with guidance.
May 12, 2025, 7:59 PM ET earnings materiality 0.70 negative item 2.02 item 9.01

Rockwell Medical Q1 net sales $18.9M (-17% YoY); net loss improves to $1.5M

Net sales fell 17% to $18.9M, driven by largest customer transitioning to another supplier.
March 20, 2025, 7:59 PM ET earnings materiality 0.80 neutral item 2.02 item 9.01

Rockwell Medical Reports Record Net Sales and First Full-Year Adjusted EBITDA Profitability in 2024

Record net sales of $101.5M in 2024, a 21% increase over 2023.
November 12, 2024, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Rockwell Medical Q3 2024 net income $1.7M, raises guidance; largest customer revenue expected to decline $31-38M in 2025

Net product sales $28.3M (+31% YoY); gross profit $6.2M (+183%); gross margin 22% vs 9%.
August 8, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Rockwell Medical Q2 net sales $25.8M (+43% YoY), net income $0.3M, raises FY 2024 guidance

Net sales $25.8M (+43% YoY); gross profit $4.6M (+341%); gross margin expanded to 18% from 6%.
July 15, 2024, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 7.01 item 9.01

Rockwell Medical amends asset purchase deal with Evoqua; affirms 2024 gross margin guidance of 14-16%

Amendment reduces First Deferred Payment by $322,260 to $2,177,740, payable in four quarterly installments through April 2025.
May 14, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01 ◈ Earnings Releases

Rockwell Medical Q1 record sales $22.7M (+15% YoY); raises 2024 guidance across all metrics

Q1 net sales $22.7M (record), up 15% YoY; ex-deferred revenue, up 25%. Gross profit $3.1M (+18% YoY).
March 21, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Rockwell Medical posts record 2023 net sales of $83.6M; achieves first-ever adjusted EBITDA profit in Q4

Q4 2023 net sales $22.1M (+14% YoY); Q4 adjusted EBITDA $0.5M vs ($0.6M) in Q4 2022, first positive quarter in company history.
January 8, 2024, 6:59 PM ET earnings materiality 0.70 neutral item 1.01 item 2.02 item 8.01 item 2.03 item 3.02 item 9.01 ◈ Earnings Releases ×2◈ Debt Financings

Rockwell Medical extends loan maturity to 2029, provides preliminary Q4 net sales $21.3M-$22.3M

Amended loan with Innovatus: $8.0M principal, interest-only 30-36 months, maturity extended from Mar 2025 to Jan 2029.
November 14, 2023, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01 ◈ Earnings Releases

Rockwell Medical Q3 revenue $23.8M, gross profit up 183% YoY; expects adjusted EBITDA profitability in Q4 2023

Net sales $23.8M, highest to-date; concentrates sales $21.6M, up 27% YoY.
September 21, 2023, 7:59 PM ET other material materiality 0.60 positive item 1.01 ◈ Material Agreements

Rockwell Medical amends DaVita supply agreement with price increase, one-time payment

DaVita agrees to increased product pricing for dialysis concentrates effective Sept 1, 2023, plus a one-time payment to Rockwell after Dec 1, 2023.
August 14, 2023, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01 ◈ Earnings Releases

Rockwell Medical acquires Evoqua concentrates, raises guidance, expects Q4 profitability

Q2 2023 net loss $3.3M ($0.18/sh) vs $5.0M loss ($0.43/sh) in Q2 2022; net sales $18.1M vs $18.7M prior year.
July 11, 2023, 7:59 PM ET M&A materiality 0.80 positive item 1.01 item 2.02 item 8.01 item 3.02 item 3.03 item 7.01 item 9.01 ◈ Material Agreements ×2◈ Earnings Releases

Rockwell Medical acquires Evoqua hemodialysis concentrates business for $16M total consideration

Acquisition for $11M cash at closing plus two $2.5M installments at 12 and 24 months.
May 15, 2023, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01 ◈ Earnings Releases

Rockwell Medical Q1 revenue $19.7M (+22.4% YoY); net loss narrows to $0.10/share

Revenue of $19.7M, up 22.4% YoY; gross profit of $2.6M vs gross loss of $0.8M in Q1 2022.

Executive changes

Appointed

Joan Lau, PhD

Class II director

RMTI · ROCKWELL MEDICAL, INC.

Effective: 2023-10-16
Filed: October 17, 2023, 7:59 PM ET

appointed Joan Lau, PhD to the Board as a Class II director

Departed

Paul McGarry

Senior Vice President, Finance and Chief Accounting Officer

RMTI · ROCKWELL MEDICAL, INC.

Effective: 2023-09-29
Filed: September 15, 2023, 7:59 PM ET

On September 13, 2023, Paul McGarry notified the Company of his decision to resign as the Company’s Senior Vice President, Finance and Chief Accounting Officer, effective September 29, 2023 (the “Effective Date”), to pursue other opportunities.

Appointed

Mark Strobeck

President and Chief Executive Officer

RMTI · ROCKWELL MEDICAL, INC.

Effective: 2022-07-01
Filed: June 22, 2022, 7:59 PM ET

the Board appointed Mark Strobeck, Ph.D. as the Company’s President and Chief Executive Officer and as a Class III Director to serve until the Company’s 2024 Annual Meeting of Stockholders and until his successor is duly elected and qualified, effective July 1, 2022

Departed

Russell H. Ellison

President and Chief Executive Officer

RMTI · ROCKWELL MEDICAL, INC.

Effective: 2022-06-30
Successor: Mark Strobeck
Filed: June 22, 2022, 7:59 PM ET

Russell H. Ellison, M.D., M.Sc., will be stepping down from his role as the President and Chief Executive Officer of the Company, effective as of June 30, 2022

Departed

John P. McLaughlin

Chairman of the Board

RMTI · ROCKWELL MEDICAL, INC.

Effective: 2022-04-01
Filed: March 21, 2022, 7:59 PM ET

On March 20, 2022, John P. McLaughlin notified the board of directors (the “Board”) of Rockwell Medical, Inc. (the “Company”) of his intent to resign as a member of the Board and as Chairman of the Board effective as of April 1, 2022.

Departed

Raymond Pratt

Chief Development Officer

RMTI · ROCKWELL MEDICAL, INC.

Effective: 2022-03-25
Filed: March 18, 2022, 7:59 PM ET

On March 14, 2022, Raymond Pratt notified the Company of his decision to resign as the Company’s Chief Development Officer, effective as of March 25, 2022.

Earnings & guidance

2026-Q1 EPS reported -$0.04 filing →

Materiality & sentiment trend

Max materiality 0.80 · Median 0.45 · Most common event other_material

14 positive 5 negative 31 neutral

source · RMTI on sec.gov